重组干扰素α-2b抗肿瘤作用的Ⅱ期临床观察

Effect of recombinant interferon alfa-2b on patients with advanced tumors:A phase Ⅱ trial

本文报道了古巴重组干扰素α-2b(HU-rIFN alfa-2b)治疗70例恶性肿瘤的结果。IFN α-2b 用法为肌肉注射,每周2次,第一周3×10~6IU/次,第2周6×10~6 IU/次;第3至8周9×10~6IU/次。在62例可评价疗效的病人中,肾癌26例,1例 CR,1例 PR(有效比2/26);黑色素癌16例,2例 PR(2/16);恶性淋巴瘤7例,4例 PR(4/7);乳腺癌13例,2例 PR(2/13);总有效率为16.1%(10/62)。主要副作用为流感样症状。包括发热、寒战、乏力、肌痛、头晕等,还有不同程度的骨髓抑制及胃肠道反应。本组的结果提示,IFN α-2b 的毒性较小,可以初步考虑作为二线药物治疗肾癌、黑色素瘤和恶性淋巴瘤。

The results of 70 patients with advanced cancer treated by interferon alfa-2b are presented herein.The drug was administered intramuscularly twice a week,the dosage being 3×10~6 IU in the first week,6×10~6 IU in the second week and 9×10~6 IU from the 3rd to the 8th week.Among 62 evaluable patients,one showed complete response and the other 9 patients experienced only par- tial response after treatment.The major side effects were flu-like syndromes,but gastro-intestinal reactions and bone marrow suppression were mild.It is concluded that interferon alfa-2b can be used as a second-line therapy for malignant lymphomas,renal cell carcinoma and malignant mala- noma.